Propanc Biopharma, Inc.

Latest News

Aug 3, 2022

Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada

Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company…

View All Press Releases

Jul 28, 2022

Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade

Jul 19, 2022

Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program

Jul 12, 2022

Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients
Latest Publication Trypsinogen and chymotrypsinogen: potent anti- tumor agents View All Publications
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
Antitumour efficacy of chymotrypsinogen and trypsinogen
In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation